Post-COVID-19 condition: a condition-level review

Record ID 32018002260
Authors' objectives: Post‒COVID-19 condition, also referred to as long COVID or post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC), among other names, is a condition characterized by new or persisting symptoms beyond the acute phase of the disease (e.g., for more than 4 or 12 weeks following an initial COVID-19 infection, clinical definition pending). People with post‒COVID-19 may experience a range of heterogenous symptoms including fatigue, shortness of breath, muscle aches, and cognitive and mental health challenges. Although the clinical pathophysiology of the condition is not yet well-defined, it is increasingly being recognized that is affects multiple organs and may have severe impacts to a person’s well-being and quality of life. CADTH, in consultation with its customers, is undertaking a Condition Level Review on post‒COVID-19. A Condition Level Review is an assessment of the evidence on a range of health technologies and emerging issues on all aspects of the condition, including prevention, identification, treatment, and management.
Project Status: Ongoing
Anticipated Publish Date: 2022
English language abstract: An English language summary is available
Publication Type: Rapid Review
Country: Canada
MeSH Terms
  • COVID-19
  • SARS-CoV-2
  • Coronavirus Infections
  • Fatigue Syndrome, Chronic
  • Rehabilitation
  • Recovery of Function
  • Time Factors
  • COVID-19
  • Coronavirus infections
  • Long COVID
Organisation Name: Canadian Agency for Drugs and Technologies in Health
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
Contact Email:

Canadian Agency for Drugs and Technologies in Health (CADTH)

This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.